Communiqués Johnson & Johnson

Actions

JNJ

US4781601046

Marché Fermé - Nyse Autres places de cotation 22:00:02 12/09/2024			Varia. 5j.	Varia. 1 janv.
164,64 ^USD	-0,11 %		-0,21 %	+5,04 %

12/09	Une unité de Johnson & Johnson dépose une demande d'autorisation de mise sur le marché en Europe pour le nipocalimab dans le traitement de la myasthénie grave généralisée	MT
12/09	L'unité J&J demande l'approbation de l'UE pour un médicament contre la maladie neuromusculaire chronique	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Johnson & Johnson Updates the Brand Identity of its MedTech Company Brands; Ethicon, DePuy Synthes, Biosense Webster, Abiomed and CERENOVUS will now go by Johnson & Johnson MedTech	12/09	AQ
TREMFYA receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease	12/09	AQ
TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease	12/09	PR
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer	10/09	AQ
Johnson & Johnson : Updates the Brand Identity of its MedTech Company Brands	10/09	PU
Johnson & Johnson - RYBREVANT plus LAZCLUZE show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer	09/09	AQ
Johnson & Johnson to Participate in the 2024 Cantor Global Healthcare Conference	06/09	AQ
Johnson & Johnson : to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference Transcript	06/09	PU
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results	05/09	BU
Johnson & Johnson : to Participate in the 2024 Wells Fargo Healthcare Conference Press Release	05/09	PU
Johnson & Johnson : to Participate in the 2024 Wells Fargo Healthcare Conference Transcript	05/09	PU
Johnson & Johnson : to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference Press Release	04/09	PU
University of Pennsylvania: A wrap for the first cohort of the Nurse Innovation Fellowship Program	02/09	AQ
Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis	30/08	AQ
Johnson & Johnson : DePuy Synthes Launches MatrixSTERNUM™ Fixation System for Enhanced Chest Stability Following Cardiac Surgery	29/08	PU
Johnson & Johnson - European Commission approves RYBREVANT in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer after failure of prior therapy	28/08	AQ
340B, AHF Blasts J&J's Illegal Rebate Plan, Urges Senate to Act	27/08	AQ
Johnson & Johnson's Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire, Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024	27/08	AQ
Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress	27/08	PR
Johnson & Johnson’s Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024	26/08	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Le directeur financier de J&J voit la valeur des partenariats technologiques

Le 12 septembre 2024 à 10:17